Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non–Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor Mutation
Journal of Thoracic Oncology, 07/16/2012
Tsai CM et al. – Combined gefitinib/antimicrotubule agents showed synergism in non–small–cell lung cancer cells harboring no sensitizing EGFR mutations. Gefitinib could enhance antimicrotubule agents effects through mechanisms not restricted to Pgp blockage.